Janux Therapeutics, Inc.
JANX · XNASCIK 1817713fmd_0ETRBTX29BW3K3Q4ND0MQYPDVYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 4 | 9 | 8 | 11 | 10 |
| Research and development | 3 | 26 | 53 | 55 | 68 | 126 |
| Operating income | (5) | (33) | (67) | (73) | (99) | (158) |
| Interest and investment income | 0 | 0 | 4 | 15 | 30 | 44 |
| Other non-operating income (expense) | (2) | 0 | 4 | 15 | 30 | 44 |
| Income tax expense | – | – | – | 0 | 0 | 0 |
| Net income | (7) | (33) | (63) | (58) | (69) | (114) |